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ARTICLE
P2X7 receptor induces mitochondrial failure
in monocytes and compromises NLRP3
inﬂammasome activation during sepsis
Juan José Martínez-García1,7, Helios Martínez-Banaclocha1,7, Diego Angosto-Bazarra1,
Carlos de Torre-Minguela 1, Alberto Baroja-Mazo1, Cristina Alarcón-Vila1, Laura Martínez-Alarcón1,
Joaquín Amores-Iniesta1, Fátima Martín-Sánchez1, Giovanni A. Ercole2, Carlos M. Martínez 3,
Ada González-Lisorge 2, José Fernández-Pacheco2, Piedad Martínez-Gil2, Sahil Adriouch 4,
Friedrich Koch-Nolte5, Juan Luján6, Francisco Acosta-Villegas2, Pascual Parrilla1,6, Carlos García-Palenciano2 &
Pablo Pelegrin 1
Sepsis is characterized by a systemic inﬂammatory response followed by immunosuppres-
sion of the host. Metabolic defects and mitochondrial failure are common in immunocom-
promised patients with sepsis. The NLRP3 inﬂammasome is important for establishing an
inﬂammatory response after activation by the purinergic P2X7 receptor. Here, we study a
cohort of individuals with intra-abdominal origin sepsis and show that patient monocytes
have impaired NLRP3 activation by the P2X7 receptor. Furthermore, most sepsis-related
deaths are among patients whose NLRP3 activation is profoundly altered. In monocytes from
sepsis patients, the P2X7 receptor is associated with mitochondrial dysfunction. Furthermore,
activation of the P2X7 receptor results in mitochondrial damage, which in turn inhibits NLRP3
activation by HIF-1α. We show that mortality increases in a mouse model of sepsis when the
P2X7 receptor is activated in vivo. These data reveal a molecular mechanism initiated by the
P2X7 receptor that contributes to NLRP3 impairment during infection.
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The response of the immune system during sepsis is acomplex dynamic process involving an initial inﬂamma-tory response followed by immune deactivation. Exacer-
bation of any of these responses compromises the life of sepsis
patients. The initial production of proinﬂammatory cytokines
aims to protect the host from invading pathogens, but it can
also damage non-infected tissues and lead to the dysfunction of
different organs and systems1. Immunosuppression after the
inﬂammatory response is a compensatory response aimed at
protecting the host from the excess production of cytokines and
other inﬂammatory factors; however, in sepsis there is a profound
leukocyte deactivation that is related to complications in critically
ill patients, and which leads to secondary fatal infections and
the majority of deaths associated with sepsis2. Changes in the
metabolism of leukocytes during sepsis are associated with the
different immune responses in sepsis, whereby the glycolytic
pathway is upregulated during the inﬂammatory response, while
defects in both glycolysis and mitochondrial respiration lead to
immunosuppression3,4. However, the molecular mechanisms in
the host that initiate and regulate immunoparalysis in human
sepsis are still poorly understood, although epigenetic modiﬁca-
tions and interleukin (IL)-33 may contribute to long-term
immunosuppression5,6.
Pattern recognition receptors in innate immune cells are able
to recognize microbial-associated or damage-associated molecules
and initiate a proinﬂammatory response7. Inﬂammasomes are
important signaling complexes formed by a subgroup of intra-
cellular pattern recognition receptors that activate caspase-1.
Caspase-1 promotes a speciﬁc type of cell death called pyroptosis,
and the release of the proinﬂammatory cytokines IL-1β, IL-18,
and the alarmin high mobility group protein B1 (HMGB1), which
are all involved in the inﬂammatory response of sepsis8–11. A
promiscuous type of inﬂammasome is formed by the nucleotide-
binding domain, leucine-rich repeat, and pyrin domain-
containing protein 3 (NLRP3) that can be activated in response
to different microbial-associated or damage-associated molecules,
as elevated extracellular concentrations of the nucleotide adeno-
sine triphosphate (ATP) signaling through the P2X purinoceptor
7 (P2X7)12,13. Upon activation, NLRP3 oligomerizes and recruits
the apoptotic speck-like protein with a caspase-activating domain
(ASC) into large oligomers, that can be found in biological ﬂuids
upon inﬂammasome activation and pyroptosis execution14,15.
The dynamic of the inﬂammatory response from proin-
ﬂammatory state to immunosuppressive state during the devel-
opment of sepsis is also reﬂected in the inﬂammasome. The
NLRP3 inﬂammasome components are overexpressed in human
leukocytes from septic patients16, and a defective function of the
NLRP3 inﬂammasome has also been found as an immunological
feature in septic patients17. Animal models of sepsis reﬂects the
initial inﬂammatory response and during this phase a deﬁciency
in NLRP3 augments survival18,19. However, the exact effects of
sepsis when induced in P2X7-receptor-deﬁcient mice are still the
cause of some debate, because different studies have found that
it can result in either higher mortality or survival20–22, thus
denoting the signiﬁcant variability in mortality in mouse mod-
els23. Therefore, further research is needed into how the P2X7
receptor controls NLRP3 inﬂammasome in sepsis, and whether
these proinﬂammatory pathways can participate in the immu-
nosuppression that occurs in human sepsis. In the present study,
we assess the activation of NLRP3 inﬂammasome by the P2X7
receptor in blood leukocytes from a cohort of clinically relevant
intra-abdominal origin sepsis patients and then carry out a
follow-up analysis of the same individuals after sepsis resolution.
Our results show that ATP-induced NLRP3 inﬂammasome does
not activate correctly in the blood leukocytes of sepsis patients.
We also identify P2X7 receptor as a modulator of mitochondrial
depolarization in monocytes, which in turn leads to NLRP3
immunoparalysis.
Results
Inﬂammasome markers are elevated in sepsis. We analyzed a
cohort of intra-abdominal origin septic patients (n= 35, Sup-
plementary Table 1), who presented elevated levels of C-reactive
protein (CRP) and procalcitonin (PCT) in their plasma 24 h after
sepsis initiation, when compared to a control group of abdominal
surgery patients that had not developed sepsis (Fig. 1a). Septic
patients presented an average acute physiology and chronic
health evaluation (APACHE II) of 18.6 ± 7.7 (range 5–52, n= 35,
average ± standard error), and a sequential organ failure assess-
ment (SOFA) of 6.4 ± 2.8 (range 2–12, n= 35), with dysfunction
of one or more vital organs together with an increase in neu-
trophils, lactate, NT-proBNP, creatinine, bilirubin, and ﬁbrinogen
(Supplementary Fig. 1 and Supplementary Tables 1 and 2). In
contrast, the amounts of hemoglobin and bicarbonate were lower
than the standards found in healthy individuals (Supplementary
Fig. 1). As expected, IL-6 and IL-8 were also higher in the plasma
of septic patients when compared to control surgery and healthy
groups (Fig. 1b). However, no IL-12, IL-4, IFNγ, IL-2, and TNF-α
were found in the plasma of septic patients with the exception of
three septic individuals who presented measurable concentrations
of TNF-α (Supplementary Table 3). On the other hand, the
inﬂammasome-related cytokines IL-1β, IL-18, and the alarmin
HMGB1 were higher in septic patients than in the control groups
(Fig. 1c). Elevated concentration of IL-18 in plasma has been
associated with mortality in sepsis24, however, the concentration
of IL-18 in our septic cohort was not associated with death (1.24
± 0.25 vs. 1.02 ± 0.17 ng/ml survival n= 23 vs. non-survival n=
12 septic patients, respectively, p= 0.7191 Mann–Whitney test,
with an area under the curve in the receiver operating char-
acteristic (ROC) analysis of 0.539 ± 0.098). We were also unable
to ﬁnd any correlation between cytokine concentration in the
plasma and sepsis mortality. The percentage of monocytes with
active caspase-1 was found to be higher in septic patients than in
healthy controls, despite the fact that monocytes from septic
patients did not present an increase in intracellular ASC speck
formation (Fig. 1d), which coincides with evidence that activation
of the NLRP3 inﬂammasome in human monocytes by the alter-
native pathway does not result in ASC specking25. However,
circulating ASC specks in plasma were higher in septic patients
than in control surgery and healthy groups (Fig. 1e), thus con-
ﬁrming our previous results showing that ASC specks in the
plasma increase during systemic inﬂammation14. During sepsis
ASC specks may be released from pyroptotic monocytes, other
activated leukocytes, endothelial cells, or cardiomyocytes, that
have all shown to release IL-1β in sepsis26,27. Altogether these
data show that during the initial phase of sepsis there is an
activation of the inﬂammasome that contributes to the cytokine
storm, thus conﬁrming previous studies, which show that septic
patients present an upregulation of inﬂammasome genes in per-
ipheral blood mononuclear cells (PBMCs)16,28 and elevated IL-18
in blood24,29.
Sepsis compromises inﬂammasome activation. Despite the
elevated concentration of IL-1β found in the plasma of septic
patients, PBMCs from septic patients presented a decreased
release of IL-1β, when LPS and ATP stimulation activated NLRP3
inﬂammasome (Fig. 2a), which corroborates a previous study
where NLRP3 activation by monosodium urate crystals was
inhibited in PBMCs from septic patients17. However, we found
that the release of IL-1β was non-detectable or very low in some
septic patients, who also presented a decreased release of HMGB1
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and formation of ASC specks in monocytes after
NLRP3 stimulation (Fig. 2b, Supplementary Fig. 2a, b). These
patients also had deﬁcient production of IL-6, TNF-α, and IL-8
(Supplementary Fig. 2c, d). The defect in NLRP3 activation in
a subset of septic patients was not due to differences in inﬂam-
masome gene expression (Supplementary Fig. 2e). A ROC ana-
lysis showed that the release of IL-1β and the formation of
ASC specks differentiated septic patients from healthy individuals
and, together with the release of HMGB1, IL-6, and TNF-α,
were sufﬁciently signiﬁcant in the ROC analysis to identify the
group with impaired NLRP3 inﬂammasome activation (Supple-
mentary Table 4), all with an area under the curve of 0.9–1.
We next found that the septic patients with immunocompro-
mised NLRP3 accounted for over 80% of the deaths registered
in the group of septic patients during their stay at the Surgical
Critical Unit (Fig. 2c, Supplementary Table 2) from day 9
onwards (Fig. 2d). Septic patients at day 1 were assessed using
different biochemical and clinical scores in order to determine
disease severity, but these tests were unable to accurately
discriminate the group with profound NLRP3 immunosuppres-
sion (Fig. 2e, f, Supplementary Fig. 2f, g). Nevertheless, patients
with severe NLRP3 suppression did present higher SOFA, but
without statistical differences (Fig. 2f). There were also no
differences in plasma cytokines, monocytes with active caspase-1,
circulating ASC-specks (Supplementary Fig. 2h), or infection
type among septic patients with profound NRLP3 immunosup-
pression (Supplementary Tables 2 and 5), although NLRP3-
immunocompromised patients suffered more often from
nosocomial infection (Supplementary Table 2). Mortality was
not the only late-outcome associated with early NLRP3-
immunocompromised septic patients, for example, the evolution
of clinical parameters, such as ΔSOFA (calculated as the change
in SOFA from day 1 to day 5) increased in these patients
(Fig. 2g, Supplementary Table 4), thus conﬁrming that ΔSOFA is
an accurate late-prognostic marker for sepsis-related deaths30,
while profound NLRP3 immunoparalysis emerged as a potential
early prognostic marker. Also, NLRP3-immunocompromised
septic patients presented a longer stay at the surgical critical unit
and required more days of mechanic ventilation (Fig. 2h), as well
as presented a non-signiﬁcant increase of renal, respiratory, and
cardiovascular dysfunction (Supplementary Table 2), suggesting
a worst outcome for the patients that presented early severe
impairment of the NLRP3 activation.
Paralysis of NLRP3 inﬂammasome during sepsis is transitory.
Plasma concentration of CRP, PCT, and IL-6 decreased after
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Fig. 1 Sepsis patients present with elevated inﬂammasome markers. a–c Plasma concentration of CRP, PCT a, IL-6, IL-8 b, IL-1β, IL-18, and HMGB1 c in
healthy controls, abdominal surgery patients within the ﬁrst 24 h after surgery and intra-abdominal origin septic patients within the ﬁrst 24 h of admission
to the surgical critical unit; dotted lines in a represent standard threshold for CRP and PCT in healthy population. d Percentage of monocytes from healthy
controls and septic patient positives for active caspase-1 labeled with FLICA (left) or positives for intracellular ASC specks (right). e Fold increase of
circulating ASC specks in the plasma of surgery controls and septic patients compared with healthy controls. Each dot represents an individual patient;
average ± standard error is represented in all panels; exact n number for each panel is presented in Source Data ﬁle; *p < 0.05; **p < 0.01; ***p < 0.001; ns,
no signiﬁcant difference (p > 0.05); Mann–Whitney test for a; Kruskal–Wallis test for b–e
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3 and 5 days of sepsis onset (Fig. 3a), thus indicating a gradual
resolution of systemic inﬂammation. However, severe NLRP3
immunoparalysis was present from days 1 to 5 in septic patients,
in whom NLRP3 activation by extracellular ATP in PBMCs
was not able to release IL-1β and whose monocytes presented
impaired intracellular ASC speck formation (Fig. 3b). Normal
release of IL-1β and ASC-speck formation was found in
non-compromised NLRP3 septic patients during the course
of the ﬁrst 5 days of sepsis (Fig. 3b). Four NLRP3 compromised
patients survived sepsis, and from them we were able to
obtain a sample from three patients once recovered. NLRP3-
immunocompromised septic patients who survived and recovered
from sepsis (n= 3) did not have detectable levels of IL-6 in
their plasma at 120 days after the septic episode (Fig. 3a, Sup-
plementary Fig. 3a), but their NLRP3 inﬂammasome could
be activated normally (Fig. 3b, Supplementary Fig. 3b). This
suggests that NLRP3 inﬂammasome impairment during sepsis
is transitory.
P2X7 receptor is upregulated in monocytes during sepsis. In
order to investigate the possible causes of NLRP3 impairment
during sepsis, we aimed to study the P2X7 receptor in monocytes
as this is the receptor for extracellular ATP, the ligand we used
to activate the inﬂammasome in monocytes from septic patients.
We ﬁrst found that the surface expression of P2X7 receptor was
higher in the monocytes of septic patients than in the control
groups (Fig. 4a, b), although the percentage of P2X7+ monocytes
was similar among septic patients and control groups (Fig. 4b).
This increase was also observed in the levels of soluble P2X7
receptor detected in plasma (Fig. 4c), which increased on the
surface of monocytes during the 5 ﬁrst days of sepsis and then
reduced upon sepsis recovery (Fig. 4d, Supplementary Fig. 3c).
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As expected, the population of CD14+CD16++ inﬂammatory
monocytes increased during sepsis (Supplementary Fig. 3d), but
the surface expression of P2X7 receptors increased in all popu-
lations of monocytes (Supplementary Fig. 3e). The increase in
surface expression of P2X7 receptors in monocytes during sepsis
was similar in both NLRP3 compromised and non-compromised
septic patients (Supplementary Fig. 3f). The stimulation of heal-
thy individual monocytes with LPS, but not IL-6, TNF-α, or
IFNγ, increased the surface expression of P2X7 receptors (Fig. 4e,
f), suggesting that bacterial infections rather than the pro-
inﬂammatory cytokines that are present during the initial phase
of sepsis are responsible for the increase in P2X7 receptor
expression observed during sepsis.
P2X7 receptor correlates with mitochondrial depolarization.
We next found that P2X7 receptor expression positively corre-
lated with the release of IL-1β after ATP stimulation in surgery
control patients and non-compromised NLRP3 septic patients
(Fig. 4g). However, in monocytes from NLRP3 compromised
septic patients, P2X7 receptor expression did not correlated with
IL-1β release (Fig. 4g), suggesting an alternative role for P2X7
receptors in sepsis. P2X7 receptors have been previously
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associated with mitochondrial damage and some studies indicate
that defects in the energy metabolism of monocytes underlay
immunoparalysis in sepsis3,4,31–33. In our cohort of septic
patients, there was an increase in monocyte mitochondrial
membrane depolarization that was reestablished when the
patients recovered from sepsis (Fig. 5a). Furthermore, the P2X7
receptors in the monocytes of NLRP3-compromised septic
patients positively correlated with mitochondrial depolarization, a
phenomenon that was negatively correlated in non-compromised
NLRP3 septic patients (Fig. 5b). P2X7 receptor stimulation in
monocytes and macrophages resulted in a fast-mitochondrial
membrane depolarization that was reversed using P2X7 receptor
antagonists and the anti-P2X7 receptor blocking nanobody 13A7
(Fig. 5c–e). Using the 14D5 nanobody, which strengthens the
response of P2X7 receptors by lowering the ATP threshold
required to activate it34, we observed an increase in mitochondrial
depolarization in response to suboptimal ATP concentrations for
P2X7 receptors (Fig. 5e). Mitochondrial membrane depolariza-
tion induced by ATP was hardly affected by the ionic ﬂow of
Ca2+ or Na+ through the P2X7 receptor (Supplementary Fig. 3g).
Mitochondrial membrane depolarization induced by ATP was
matched by an increase in mitochondrial ROS production in the
monocytes (Fig. 5f, Supplementary Fig. 3h) and was higher in
septic patients than in the control surgery group (Fig. 5g).
Mitochondrial depolarization induced by ATP occurred inde-
pendently of LPS-priming and the NLRP3 inﬂammasome
(Fig. 5h). Mitochondrial depolarization was also conﬁrmed using
the green MitoTracker mitochondrial dye, which stains to a
greater or lesser extent depending on the mitochondrial mem-
brane potential (Supplementary Fig. 4a). However, this change on
the mitochondrial membrane potential did not damage the
mitochondria integrity, as is demonstrated by the absence of
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cytochrome c in the cytosol fraction after P2X7 receptor activa-
tion (Supplementary Fig. 4b). This was further conﬁrmed by
electron microscopy, which showed no damage to the mito-
chondria when ATP was applied, and instead revealed a swelling
of the mitochondria that was dependent on P2X7 receptor acti-
vation, this was evidenced by the use of a speciﬁc P2X7 receptor
antagonist that reversed it (Supplementary Fig. 4c). This
mitochondrial swelling induced after P2X7 receptor activation
was also observed by staining with the mitochondria marker
Tomm20 (Supplementary Fig. 4d). These data suggest that the
activation of P2X7 receptors in resting monocytes and macro-
phages results in mitochondrial depolarization, swelling, and
ROS production, but not in fragmentation or damage of the
mitochondrial structure.
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P2X7 receptors impairs NLRP3 inﬂammasome activation.
Having found that stimulating P2X7 receptors in unprimed
monocytes and macrophages induced mitochondrial membrane
depolarization, we then found simultaneously that NLRP3
inﬂammasome activation was impaired after LPS-priming and
subsequent ATP or nigericin treatment (Fig. 6a–c). Stimulation
of the P2X7 receptor before NLRP3 priming and activation
decreased the formation of intracellular ASC specks (Fig. 6a)
and impaired the release of IL-1β (Fig. 6b, c). This effect was
reverted using a speciﬁc antagonist for P2X7 receptor (Supple-
mentary Fig. 5a). P2X7-receptor-deﬁcient macrophages did not
present NLRP3 inﬂammasome inhibition when ATP was
applied before LPS priming (Fig. 6c), suggesting that activation of
P2X7 receptor before LPS priming decrease NLRP3 inﬂamma-
some activation. NLRP3 impairment was independent of K
+-efﬂux through the P2X7 receptor (Supplementary Fig. 5b). This
result was similar to the response of monocytes isolated from
profoundly NLRP3-immunocompromised septic patients, in
whom P2X7 receptor expression correlated with mitochondrial
dysfunction (Fig. 5b). IL-1β release was also reduced when
mitochondrial membrane depolarization was induced by FCCP
or antimycin A, and this effect was independent of the P2X7
receptors, given that P2X7-receptor-deﬁcient macrophages also
released less IL-1β in response to FCCP or antimycin A (Fig. 6d,
Supplementary Fig. 5c). ATP, FCCP, and antimycin A treatment
did not induce cell death (Supplementary Fig. 5d, e). Gene
expression for Nlrp3 and Il1b was partially reduced when the
P2X7 receptors were activated before LPS priming in wild
type mice, but not in P2X7-receptor-deﬁcient macrophages
(Fig. 6e), suggesting that P2X7 activation could also induce a
possible defect in inﬂammasome priming. Similarly, mitochon-
drial membrane depolarization induced by antimycin A reduced
Nlrp3 and Il1b gene induction by LPS (Supplementary Fig. 5f).
To determine if P2X7-receptor activation before bacterial
priming was had a signiﬁcant effect on decreasing survival rates
during sepsis, we performed cecal ligation and puncture (CLP) in
wild type and P2rx7−/− mice with an initial i.p. ATP injection.
We found a signiﬁcant reduction in the survival of P2rx7−/−mice
compared to wild type animals after CLP (Supplementary Fig. 5g),
which is consistent with previous studies21,22. Injection of ATP
before CLP signiﬁcantly decreased the survival rates of wild type
mice, but not of P2rx7−/−mice (Fig. 6f). P2X7 receptor activation
in vivo before infection decreased the release of IL-1β into the
mouse peritoneum (Fig. 6g) and prevented effective control of
the infection as the bacterial load in the blood increased in
animals pre-treated with ATP (Fig. 6g).
NLRP3 impairment induced by P2X7 receptor activation in
cultured macrophages was transitory, and mitochondrial mem-
brane potential was restored after washing extracellular ATP for
4–12 h (Fig. 7a), as was the ability of macrophages to produce IL-
1β normally after NLRP3 activation (Fig. 7b). The antioxidant
pyrrolidine dithiocarbamate (PDTC) was able to protect against
ATP-induced mitochondrial-membrane depolarization (Fig. 7c)
and restored the production of IL-1β after stimulating the P2X7
receptors with ATP before LPS-priming and NLRP3 activation
(Fig. 7d), thus suggesting that NLRP3 impairment induced by
P2X7-receptor activation could be mediated by mitochondrial
dysfunction. Given that hypoxia-inducible factor (HIF)-1α has
been described as an important factor for the metabolic
reprogramming of myeloid cells during sepsis, we next analyzed
how P2X7 receptors could be controlling HIF-1α. We found that
P2X7 receptor activation by ATP increased HIF-1α expression in
human monocytes (Fig. 7e). However, FCCP and antimycin A did
not increase HIF-1α (Supplementary Fig. 5h), which suggests that
the P2X7 receptor action was differentially rather than directly
targeting complex III or directly transporting protons across
mitochondrial inner membrane. HIF-1α expression induced by
ATP treatment was dependent on the P2X7 receptors and
mitochondrial membrane depolarization, since P2X7 antagonist
AZ116 and PDTC treatment during ATP stimulation were both
able to prevent it (Fig. 7e). Blocking HIF-1α with echinomycin
restored the production of IL-1β after the P2X7 receptors were
stimulated with ATP before LPS-priming and NLRP3 stimulation
(Fig. 7f). HIF-1α was expressed in septic patients and in the
surgery control group (Fig. 7g), and the higher HIF-1α expression
in NLRP3 non-immunocompromised patients correlated with a
lower IL-1β release (Fig. 7h). In conclusion, our data support
a model in which the P2X7 receptors affect mitochondria and
impair NLRP3 inﬂammasome in monocytes, a process that could
contribute to immunosuppression in septic patients.
Discussion
Sepsis remains the leading cause of death in critical care units35.
Our study reveals that during the initial inﬂammatory response
in sepsis, septic patients present an early impairment of the
NLRP3 inﬂammasome that is associated with higher mortality.
The expression of P2X7 receptors increased in monocytes from
septic patients and correlated with mitochondrial membrane
dysfunction, and not with the secretion of IL-1β. Mechanistically,
P2X7 receptor activation in monocytes before microbial-
stimulation resulted in mitochondrial damage, HIF-1α expres-
sion, and impairment of the NLRP3 inﬂammasome activation.
Fig. 5 P2X7 receptor induces mitochondrial membrane depolarization. a Mitochondrial membrane potential from blood monocytes stained with JC-10 in a
control healthy donor (left), in a septic patient at day 1 (middle), and from healthy controls, abdominal surgery, and septic patients at day 1 or 120 (right);
PE− cells represent the monocytes with mitochondrial depolarization. b Correlation between the percentage of monocytes with mitochondrial membrane
depolarization and the quantiﬁcation of P2X7 receptor MFI in monocytes from the septic patients; IC: immunocompromised septic patients. c Kinetics of
mitochondrial depolarization after ATP (3 mM) stimulation of LPS-primed BMDMs incubated or not with the P2X7 receptor antagonist A438079 (10 μM).
d Percentage of human monocytes from healthy donors with mitochondrial membrane depolarization after ATP (3 mM, 30min) stimulation and incubated
or not with the P2X7 receptor antagonist AZ11645373 (10 μM). e Percentage of mouse BMDMs with mitochondrial membrane depolarization after ATP
stimulation at the indicated concentrations for 30min and incubated or not with anti-P2X7 nanobodies (13A7, blocking nanobody; 14D5, potentiating
nanobody; each at 200 nM). f Mitochondrial ROS production from human monocytes isolated from healthy donors after ATP (3mM, 30min) stimulation.
gMitochondrial ROS from human monocytes isolated from surgery controls and septic patients (white bar); right bars separate the group of septic patients
into NLRP3 non-immunocompromised (gray bar) and immunocompromised (blue bar). hMitochondrial membrane depolarization from wild-type or knock-
out BMDMs as indicated primed or not with LPS (4 h) and treated for 30min with ATP (3mM, green bars), ATP and A438079 (10 μM, white bars),
or antimycin A (5 μM, gray bars). Each dot represents an individual patient in a, b, g, or an individual healthy donor in d, f, a single independent experiment
in e, h, or average+ SEM of two independent experiments in c; average ± standard error is represented in panels a (right), c–h; exact n number for each
panel is presented in Source Data ﬁle; *p < 0.05; **p < 0.01; ***p < 0.001; ns, no signiﬁcant difference (p > 0.05); Pearson correlation was used in b;
Mann–Whitney test was used in f; and Kruskal–Wallis test was used in a, g, h
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10626-x
8 NATURE COMMUNICATIONS |         (2019) 10:2711 | https://doi.org/10.1038/s41467-019-10626-x | www.nature.com/naturecommunications
ecba
d
f
g
0
ND
10
30
20 *
ns
Wild type
*
P2rx7 –/–
N
lrp
3/
Hp
rt1
0
2
1
ATP-pre
LPS:
–
+
+
+
**
ns
–
+
–
–
–
–
+
+
ATP-pre
LPS:
–
+
+
+
–
+
–
–
–
–
+
+
Il1
b/
Hp
rt1
0
4
2
10
8
6
**
ns
AS
C 
sp
ec
kin
g
m
o
n
o
cy
te
s 
(%
)
0
20
10
40
30
ATP-pre
LPS:
ATP-post
Nigericin:
–
–
–
–
+
–
–
–
*
–
+
–
–
+
+
–
–
–
+
+
–
+
+
+
–
–
+
–
+
+
+
–
+
ATP-pre
LPS:
ATP-post
Nigericin:
–
–
–
–
+
–
–
–
–
+
–
–
+
+
–
–
–
+
+
–
+
+
+
–
–
+
–
+
+
+
–
+
ATP-pre
LPS:
ATP-post
Nigericin:
–
+
+
–
+
+
+
–
–
+
–
+
+
+
–
+
–
+
+
–
+
+
+
–
–
+
–
+
+
+
–
+
*
IL
-1
β (
ng
/m
l)
IL
-1
β (
ng
/m
l)
IL
-1
β (
ng
/m
l)
0
3
2
1
5
4
p = 0.057
*
***
**
**
*
0
5
25
20
15
10
FCCP:
Antimycin A:
LPS + nigericin:
–
–
+
+
–
+
–
+
+
–
–
+
+
–
+
–
+
+
***
Su
rv
iva
l (%
)
20
100
80
60
40
CLP,
vehicle
Wild type
CLP,
ATP
Sham, vehicle
CLP,
vehicle
CLP,
ATP
Sham, vehicle
Sham, ATP
Su
rv
iva
l (%
)
Time (h)
0
0
20
20
100
100
80
80
60
60
40
40
P2rx7 –/–
ns
IL
-1
β (
ng
/m
l)
0
1.0
0.75
0.50
0.25
+
–
–
–
+
–
–
+
+
Sham:
CLP:
ATP:
+
–
–
–
+
–
–
+
+
Sham:
CLP:
ATP:
Ba
ct
er
ia
l l
oa
d
(C
FU
/m
l)
0
100
20
10
5
Wi
ld 
typ
e
P2
rx7
–
/– Wi
ld 
typ
e
P2
rx7
–
/–
Wi
ld 
typ
e
P2
rx7
–
/–
Fig. 6 P2X7 receptor stimulation impairs the NLRP3 inﬂammasome in monocytes. a, b Percentage of monocytes with ASC-specks (a) and release of IL-1β
from PBMCs (b) isolated from healthy donor blood samples treated with ATP (3mM, 30min; ATP-pre), then washed and primed with or without LPS
(1 μg/ml, 2 h) and then treated for 20min with ATP (3mM; ATP-post) or nigericin (10 μM) as indicated. c IL-1β release from wild type or P2rx7−/−
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experiment (c, d), a sample from an individual healthy donor (a, b, e) or a single mouse (g); average ± standard error is represented in panels a–e, g; exact
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a, b, d, e; Kruskal–Wallis test was used for c; Log-rank test for f
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10626-x ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2711 | https://doi.org/10.1038/s41467-019-10626-x |www.nature.com/naturecommunications 9
Sepsis causes a systemic inﬂammatory response driven by the
production of proinﬂammatory cytokines. IL-6 and IL-18 have
been proposed as potential biomarkers for septic patients24,36–39.
Our study demonstrates that at day 1, the inﬂammasome-related
cytokines IL-1β and IL-18, the alarmin HMGB1 and circulating
aggregates of ASC are higher in the blood of septic patients of
intra-abdominal origin, which coincides with previous publica-
tions that found elevated inﬂammasome gene expression in
monocytes and circulating IL-18 during sepsis24,29. However,
while IL-18 concentration has been positively associated with
mortality in sepsis24, IL-18 measured in our cohort of septic
patients did not correlate with mortality. Also, our study did not
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ﬁnd a signiﬁcant increase in inﬂammasome genes in the PBMCs,
in contrast with other studies that have found an increase in
NLRP3, CASP1, and PYCARD16,28. These differences could be
due to the inclusion of patients with lung infections16 or to dif-
ferent ranges of etiologies among the septic patients enrolled in
other studies24,28, in contrast to our study, which focuses on a
well-deﬁned population of intra-abdominal septic patients. Dif-
ferent studies have demonstrated that human blood monocytes
from septic patients responded differently to ex vivo bacterial
endotoxin challenge4,40–45, and only one study has found an
impaired inﬂammasome response in septic patients17. The ele-
vated risk of late-deaths in sepsis is thought to be related to the
immunosuppressive state of leukocytes in these patients2,41,46. In
the present study, we report a differential activation of the NLRP3
inﬂammasome in septic patients, and have found that patients
with profound NLRP3 deactivation accounted for most late
deaths. These patients also presented impaired production of
other cytokines when PBMCs were stimulated ex vivo, suggesting
a general suppression of innate immunity. Although the NLRP3-
immunocompromised septic cohort that we studied is relatively
small, NLRP3 function accurately identiﬁed patient death over
other early clinical scores. Impairment of NLRP3 inﬂammasome
activation was found as early as within the ﬁrst 24 h after patient
enrollment in our study, when there were high levels of inﬂam-
matory and inﬂammasome markers in the blood. This supports
previous data demonstrating that the release of IL-1β is com-
promised in ex vivo LPS-stimulated PBMCs collected after 2 h
of intravenous LPS infusion in healthy volunteers17, and that
within 24 h of the onset of human sepsis NLRP1 gene expression
decrease in monocytes47. Therefore, NLRP3 inﬂammasome
deactivation in sepsis overlap a systemic proinﬂammatory
response, which supports the idea that in critically injured
patients pro-inﬂammatory and anti-inﬂammatory responses
could coexist at the same time48.
Blood monocytes are important cells in the development of an
immunocompromised state in sepsis because they not only
acquire a deactivation phenotype but are also involved in sup-
pressing lymphocyte function49,50. The immunocompromised
state of these cells has been found to be due to defects in the
metabolism of septic monocytes, including important paralysis of
mitochondria with a parallel reduction of oxygen
consumption3,4,31,32. Furthermore, the mitochondria of myeloid
cells undergo adaptations in the respiratory chain upon sensing
bacteria51, and HIF-1α appears as a key factor for the metabolic
reprogramming of myeloid cells during sepsis6,44,52,53. Here we
conﬁrm that monocytes from septic patients present dysfunc-
tional mitochondria, as is evidenced by the depolarization of the
mitochondrial membrane, but without any structural damage. It
is known that the purinergic P2X7 receptor, a receptor for
extracellular ATP and a strong activator of NLRP3 inﬂamma-
some, also stimulates the induction of HIF-1α in different non-
myeloid cells12,54–56, and we conﬁrm this in human monocytes in
the present study. We found elevated P2X7 receptor expression in
the surface of monocytes from septic patients when compared to
monocytes from control groups, and P2X7 receptor expression
in septic patients’ monocytes was correlated with increased
mitochondrial dysfunction. This conﬁrms previous data in
recombinant HEK293 cells where activation of the P2X7 receptor
and subsequent increase of intracellular Ca2+ induce rapid
mitochondrial depolarization and swelling33. However, in our
study mitochondrial depolarization in macrophages was slightly
dependent on increased intracellular Ca2+, suggesting that other
P2X7 receptor signaling in this cell type may lead to mitochon-
drial depolarization. This effect was independent of LPS-priming
and NLRP3 inﬂammasome, thus ruling out possible mitochon-
drial damage as a consequence of caspase-1 activation57. When
P2X7 receptors were triggered in resting monocytes and macro-
phages, it decreased the response of these cells to further activate
the NLRP3 inﬂammasome, thus inducing a deactivation state in
the monocyte similar to the state found in immunocompromised
septic patients. This was also supported by a mouse model of
sepsis, in which P2X7-receptor-deﬁcient mice had a lower sur-
vival rate than wild type animals, thus corroborating previous
work using the CLP model or i.v. injection of E. coli21,22. We also
found that activation of P2X7 receptors in vivo before sepsis
increased mouse mortality, which is similar to previous obser-
vations regarding LPS-induced mortality19. However, one pre-
vious study found that the P2X7-deﬁcient mice present increased
survival rates after the CLP model20. This controversy not only
demonstrates the variability of the CLP model23, but also high-
lights the fact that sepsis survival is a ﬁne balance between the
degree of inﬂammasome-activation and downstream cytokine
production. This process is critically modulated by the time of
P2X7 receptor activation, and this may lead to the repression or
induction of the NLRP3 inﬂammasome. This effect was depen-
dent on HIF-1α after mitochondrial dysfunction in monocytes
and macrophages when analyzed in vitro. In this situation, P2X7
receptor activation prevents and does not induces, NLRP3
inﬂammasome activation. Similarly, it is known that in M2
macrophages ATP is able to prevent NLRP3 inﬂammasome
activation, but this effect was independent of P2X7 receptors58.
An increase in extracellular ATP concentration due to compli-
cations during surgery or as consequence of different treat-
ments59, could activate P2X7 receptors before or during the early
phase of an infection, and might contribute to the development
of immunosuppression by impairing the NLRP3 inﬂammasome.
In conclusion, we found that activation of NLRP3 inﬂamma-
some in monocytes is compromised in septic patients, where
P2X7 receptor expression is associated with mitochondrial dys-
function but not with IL-1β release. Activation of P2X7 receptors
in resting myeloid cells before priming with microbial-associated
molecules impaired NLRP3 inﬂammasome activation via mito-
chondrial damage and HIF-1α production. Restoration of P2X7
receptor expression levels and NLRP3 inﬂammasome activation
in monocytes could be a good indicator of immune recovery in
septic patients. Therapies aiming to decrease extracellular ATP or
to block the P2X7 receptor at early time points, could help pro-
vide individualized treatment for septic patients and improve
survival rates among patients.
Methods
Human clinical samples. The clinical ethics committee of the Clinical University
Hospital Virgen de la Arrixaca (Murcia, Spain) approved this study and its pro-
cedures (reference number PI13/00174). The samples and data from patients
included in this study were provided by the Biobanco en Red de la Región de
Murcia (PT13/0010/0018), which is integrated into the Spanish National Biobanks
Network (B.000859). All study procedures were conducted in accordance with the
declaration of Helsinki. Whole peripheral blood samples were collected after
receiving written informed consent from intraabdominal sepsis patients (n= 35,
Supplementary Table 1) at the Surgical Critical Unit from the Clinical University
Hospital Virgen de la Arrixaca (Murcia, Spain) after 1, 3, 5, and 120 days of sepsis
development, day 1 being the blood sample obtained within 24 h of the diagnosis of
sepsis. Acute physiology and chronic health evaluation II (APACHE II) and SOFA,
different clinical, microbiological, hemodynamic, and biochemical determinations
were routinely evaluated in all septic patients at different days by the Clinical
University Hospital Virgen de la Arrixaca Surgical Critical Unit, Clinical Analysis
and Microbiology Units. All the septic patients included in this study met the
deﬁnition for severe sepsis or septic shock that was valid at the time of sample and
data collection60. The inclusion criteria for septic patients were patients diagnosed
with intra-abdominal origin sepsis conﬁrmed by exploratory laparotomy, with at
least two diagnostic criteria for sepsis (fever or hypothermia; heart rate >90 beats
per minute; tachypnea, leukocytosis, or leukopenia) and multiple organ dysfunc-
tion deﬁned as physiological dysfunction in two or more organs or organ
systems60. We excluded patients who were immunocompromised or presented
immunodeﬁciency (including antineoplastic treatments during the month previous
to the septic episode). We also excluded terminal oncologic and hematologic
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neoplastic patients, as well as patients that had a delay of >24 h from intra-
abdominal sepsis diagnosis to surgery, patients who spent <24 h in the Surgical
Critical Unit, those whose infection was not cleared by the surgery and patients
who presented another septic focus different from the abdominal focus. We also
analyzed whole peripheral blood samples from healthy volunteers (n= 11) and
abdominal surgery patients, who had not developed sepsis (n= 14, Supplementary
Table 1).
CLP model. All animal work was in accordance with Spanish national (RD 53/
2013) and EU (86/609/EEC and 2010/63/EU) legislation. The University of Murcia
Animal Research Ethical Committee approved animal procedures (ref. 5/2014) and
then the Animal Health Service of the General Directorate of Fishing and Farming
of the Council of Murcia (Servicio de Sanidad Animal, Dirección General de
Ganadería y Pesca, Consejería de Agricultura y Agua Región de Murcia) approved
animal procedures with ref. A1320140201. CLP-induced sepsis was performed in
C57BL/6 (WT, wild-type) and P2X7R-deﬁcient (P2rx7−/−) mice in C57BL/6
background. Thirty minutes before CLP, a group of mice received an intraper-
itoneal injection of ATP (0.5 mg/g) or saline vehicle. Laparotomy was performed to
isolate the cecum of mice anesthetized with isoﬂurane. Approximately 2/3 of the
cecum was ligated with a 6–0 silk suture and punctured twice through-and-through
with a 21 gauge needle. The abdominal wall and incision were then closed with
6–0 silk suture. Sham-operated animals underwent laparotomy without ligation or
puncture of the cecum. Buprenorphine (0.3 mg/kg) was administered intraper-
itoneally at the time of surgery and mice were monitored continuously until
recovery from anesthesia. For sample collection, 24 h after the procedure, animals
were euthanized with CO2 inhalation, and peritoneal lavages were performed with
4 ml of sterile saline and then blood was collected from the thoracic aorta. Serum
and centrifuged (cell free) peritoneal lavages were stored at −80 °C until further
analysis. Serum was diluted serially in sterile physiologic saline and plated and
cultured on agar plates at 37 °C for 24 h. Then the number of bacterial colonies was
counted and expressed as CFU/ml of serum.
Cells and treatments. Human PBMCs were isolated from blood within one hour
after extraction using Ficoll histopaque 1077 (Sigma-Aldrich). BMDM were
obtained from wild-type, Nlrp3−/−, Casp1/11−/−, and P2rx7−/− mice by differ-
entiating bone marrow cells for 7 days in DMEM (Lonza) supplemented with 25%
of L929 medium, 15% fetal calf serum (FCS, Life Technologies), 100 U/ml peni-
cillin/streptomycin (Lonza), and 1% L-glutamine (Lonza)61. THP-1 cells were
maintained in RPMI1640 media with 10% FCS and 2mM GlutaMAX (Life
Technologies). Cells were treated either in tissue culture plates or directly in ﬂow
cytometry tubes with ATP (Sigma-Aldrich), antimycin A (Sigma-Aldrich), or
FCCP (Sigma-Aldrich) in the presence or absence of PDTC (Sigma-Aldrich) or
echinomycin (Sigma-Aldrich) in E-total buffer (147 mM NaCl, 10 mM HEPES, 13
mM glucose, 2 mM CaCl2, 1 mM MgCl2, and 2 mM KCl, pH 7.4) and then washed
and stimulated with E. coli LPS O55:B5 in their respective complete media. In some
experiments, PBMCs were treated with recombinant human IL-6, TNF-α, or IFNγ
(PeproTech). After LPS treatment, cells were incubated with P2X7-modulating
nanobodies34, the speciﬁc P2X7 receptor antagonist A438079 or AZ11645373
(Tocris), and then subsequently stimulated with ATP or nigericin (Sigma-Aldrich)
in E-total buffer for 20–30 min as speciﬁed in the ﬁgure legends. Times and
concentrations for the reagents used are speciﬁed in the ﬁgure legends. 23 out of
the 35 septic patients included in this study (65.7%) were able to provide enough
blood samples for in vitro PBMC stimulation.
ELISA and multiplexing assay. Cytokines and soluble P2X7 in plasma were
measured by ELISAs from eBioscience, IBL International, R&D Systems, Cusabio
(for soluble P2X7), and MBL following the manufacturers’ indications and read in
a Synergy Mx (BioTek) plate reader. Multiplexing was performed using the
Cytometric Bead Array from Becton Dickinson Biosciences following the manu-
facturer indications, and were analyzed in a BD FACS Canto.
Flow cytometry. Intracellular ASC-speck formation was evaluated by the Time of
Flight Inﬂammasome Evaluation in CD14+ monocytes using a polyclonal
unconjugated rabbit anti-ASC (N-15)-R antibody (catalog sc-22514-R, SantaCruz
Biotechnology), and a secondary monoclonal donkey anti-rabbit antibody Alexa
Fluor-488 (catalog A21206, Life Technologies), both at 1:1000 dilution. HIF-1α
expression was detected in CD14+ monocytes using Alexa Fluor-647 mouse anti-
human HIF-1α (BD Biosciences, Clone 54, catalog 565924) at 10 μl per 5 × 105
cells, using a transcription factor buffer set (BD Biosciences) following manu-
facturer’s instructions. Cells treated in the same conditions and without staining for
HIF-1α were used as a background control. Monocytes were determined from
PBMCs by CD3− CD14+ selection, and P2X7 receptor surface expression was
determined in CD16−/+/++ monocytes using the monoclonal anti-P2X7 L4 clone
conjugated with APC62. Active caspase-1 was measured in monocytes using the
speciﬁc ﬂuorescent probe FLICA-660 Caspase-1 Assay Kit (Immunochemistry
Technologies) following the manufacturer’s instructions. Production of ROS was
measured in monocytes using the red mitochondrial superoxide indicator Mito-
SOX (Life Technologies) following the manufacturer’s instructions. For gating
strategy used in ﬂow cytometry see Supplementary Figs. 6 and 7. The detection of
extracellular particles of ASC was performed on 0.5 ml of human plasma by ﬂow
cytometry using a polyclonal unconjugated rabbit anti-ASC (AL177) antibody
(catalog AG-25B-0006-C100, Adipogen) at 1:1000 dilution, and a secondary Alexa
Fluor 647F(ab′) fragment of goat anti-rabbit IgG (H+L) (catalog A21246, Life
Technologies) at 1:2000 dilution14. For the determination of ASC specks, HIF-1α
expression, and FLICA, monocytes were selected using anti-CD14 PE (clone 61D3,
catalog 50-0149-T025, Tonbo biosciencies) or anti-CD14 APC-H7 (clone MφP9,
catalog 560180, BD Biosciences). For MitoSOX determination monocytes were
selected using anti-CD33 APC-vio770 (clone REA775, catalog 130-111-139, Mil-
tenyi). Samples were analyzed by ﬂow cytometry using FACS Canto (BD Bios-
ciences) and the FCS express software (De Novo Software). For multiparametric
ﬂow cytometry experiments a ﬂuorescence minus one (FMO) control was included
following recommendation of the recent ﬂow cytometry guides for immunological
studies63.
Mitochondrial membrane potential. Mitochondrial membrane potential was
measured using the JC-10 dye (Abcam) in BMDMs with a Sinergy Mx plate reader
(BioTek) or by ﬂow cytometry using the BD FACS Celesta ﬂow cytometer (BD
Biosciences), or in human monocytes (CD14+ labeled with anti-CD14 APC-H7,
clone MφP9, catalog 560180, BD Biosciences) using FACS Canto (BD Biosciences),
following the indications of manufacturer.
LDH assay. Presence of LDH in cell-free supernatants was measured using the
Cytotoxicity Detection kit (Roche) following the manufacturer’s instructions.
Quantitative reverse transcriptase-PCR analysis. Total RNA was extracted
from cells using the RNeasy Mini kit (Qiagen), followed by reverse transcription
using iScript cDNA Synthesis (Bio-Rad). The mix SYBR Premix ExTaq (Takara)
was used for quantitative PCR in iCycler MyiQ thermocycler (Bio-Rad). Speciﬁc
validated primers for quantitative PCR were purchased from Sigma-Aldrich61.
Relative gene expression levels were calculated using the 2−ΔCt method normal-
izing to Hprt1 expression as endogenous control.
Statistical analysis. Statistics were calculated with Prism software (GraphPad
Software Inc.). Normality of the samples was determined with D’Agostino and
Pearson omnibus K2 normality test and samples did not follow a Gaussian dis-
tribution. Outliers from data sets were identiﬁed by the ROUT method with Q=
1%. Non-parametric Mann–Whitney test was used to analyze differences between
two non-paired groups, Wilcoxon test was used to compare two paired groups, and
Kruskal–Wallis test was used to analyze differences among three or more groups.
The χ2-test was used to determine whether there was a signiﬁcant difference
between different clinical variables among groups of septic patients. Kaplan–Meier
was used to estimate the survival of septic patients and the log-rank test was used to
compare the survival distributions of samples.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data used to construct Figs. 1–7 are presented in the Source Data ﬁle. All other data are
available from the corresponding author upon reasonable request.
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